Morphic Holding (MORF) Stock Price
Morphic Holding Price
Revenue at Morphic Holding has contracted by 31.1% per year over the past 5 years to 521,000.00 USD. For Morphic Holding, the net margin of -29,192.9% is down versus -255.2% a few years ago. The consensus 12-month price target for Morphic Holding is 58.14 USD, about 2.0% above where the stock trades today. Of 15 analysts, 7 rate the stock a buy — an overall Hold consensus.
Morphic Holding stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Morphic Holding business model & stock analysis
Frequently asked questions about Morphic Holding
The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.
Morphic Holding Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Morphic Holding Inc in the market include pharmaceutical companies such as Biogen Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the biotechnology industry and focus on developing innovative therapies and drugs for various conditions. By being aware of the competitive landscape, investors and individuals interested in Morphic Holding Inc can gain insights into the market dynamics and potential challenges the company may face.
Morphic Holding Inc is a reputable company specializing in the field of biotechnology. Founded in 2014, Morphic focuses on developing integrin-targeted therapeutics for chronic inflammatory and autoimmune diseases. The company boasts a talented team of scientists and researchers dedicated to advancing new treatment options. Morphic has collaborated with several renowned institutions and pharmaceutical companies to develop novel drugs targeting specific integrins, thus making significant strides in the field of biopharmaceuticals. With their rich history and strong track record, Morphic Holding Inc continues to make promising advancements in the biotechnology industry, showcasing their commitment to improving global healthcare.
Morphic Holding Inc has achieved significant milestones since its establishment. The company successfully completed its initial public offering (IPO) and listed on the Nasdaq stock exchange under the ticker symbol MORF. Moreover, Morphic Holding Inc has made notable advancements in its drug discovery research and development programs, particularly in the field of integrin-targeted therapies. This has allowed the company to progress multiple drug candidates into various stages of clinical trials, highlighting its dedication to addressing unmet medical needs. Morphic Holding Inc continues to strive for excellence in the pharmaceutical industry, constantly pushing boundaries to bring innovative treatments to patients worldwide.
Morphic Holding Inc is primarily present in the United States.
Morphic Holding Inc represents a set of core values and corporate philosophies that drive their operations. With a focus on innovation, they are committed to pushing boundaries and delivering groundbreaking solutions in the biopharmaceutical industry. As a company, Morphic Holding Inc values integrity, transparency, and ethical practices, ensuring they uphold the highest standards in all their endeavors. By fostering a collaborative environment, they encourage teamwork, diverse perspectives, and a shared passion for making a positive impact on patients' lives. Morphic Holding Inc's dedication to excellence and patient-centric approach defines their identity and drives their pursuit of pioneering therapeutic advancements.
Analysts currently set an average price target of 59.60 USD for the Morphic Holding stock (median: 58.14 USD), implying +4.6 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Morphic Holding stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Morphic Holding to generate revenue of 408,000.00 USD and earnings per share of -5.40 USD.
Converted at the current exchange rate, the Morphic Holding share trades at 50.82 EUR (56.99 USD).
The Morphic Holding share (MORF) is listed on 4 stock exchanges, including: NASDAQ (MORF), Frankfurt (31Y.F), München (31Y.MU), Düsseldorf (31Y.DU).
Morphic Holding Inc is a US-based biotechnology company focused on the discovery and development of drugs based on the science of integrin pharmacology. The company was founded in 2015 and is listed on the Nasdaq stock exchange under the symbol "MORF". This article will describe the business model of Morphic Holding Inc. Integrin pharmacology is a novel therapeutic strategy that specifically targets integrins to modulate specific cell/tissue interactions. Integrins are protein molecules on the surface of cells that are responsible for cell adhesion, cell migration, and signal transduction, making them important targets for drug development. Morphic Holding Inc has a strong portfolio of proprietary molecules that modulate integrins to treat diseases such as inflammatory bowel disease, fibrosis, cancer, pain, and autoimmune diseases. The company also has strategic partnerships with leading pharmaceutical companies such as AbbVie, Janssen, and Schrödinger to further intensify their research. Morphic's business model involves developing innovative drugs based on integrin pharmacology and licensing them to pharmaceutical companies. The company pursues a dual strategy by independently advancing its own pipeline while also demonstrating the value of its technology platform through collaborations. Morphic's product portfolio includes several drugs in development targeting fibrosis, inflammatory bowel disease, cancer, and autoimmune diseases. The lead product candidate, MORF-057, is a selective integrin α4β7 antagonist developed for the treatment of inflammatory bowel disease and is currently in Phase 2 clinical trials. Furthermore, the company recently completed the acquisition of Morphic Therapeutic Europe Limited, a company focused on researching and developing integrin-mediated tumor metastasis blockade. This acquisition expands Morphic's portfolio with innovative preclinical drug candidates for the treatment of cancer based on integrins. In summary, Morphic Holding Inc has an innovative business model based on integrin pharmacology. The company develops drugs targeting a variety of diseases by specifically modulating integrins. Their products are currently in development and have the potential to achieve significant therapeutic advancements. Through strategic partnerships and acquisitions, the company is further expanding its position in the biotechnology sector.
The expected revenue of Morphic Holding is 408,000.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Morphic Holding is -226.92 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Morphic Holding is currently -10.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Morphic Holding stock.
The price-to-sales ratio (P/S) of Morphic Holding is currently 5,866.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Morphic Holding stock.
The Eulerpool Quality Score for Morphic Holding is 2/10.
The ISIN of Morphic Holding is US61775R1059. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Morphic Holding is A2PLX9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Morphic Holding is MORF. The ticker symbol is used to trade Morphic Holding shares on the stock exchange.
Morphic Holding stock
Morphic Holding Peer Group
Morphic Holding Ticker
Morphic Holding FIGI
All fundamentals and in-depth analysis of Morphic Holding
Our stock analysis for Morphic Holding stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Morphic Holding. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.